Bsi-201

[Rich66]

PRESS RELEASE
BiPar Sciences Receives 2008 Emerging Technology Award in Biotechnology





Last update: 9:30 a.m. EST Dec. 10, 2008


BRISBANE, Calif., Dec 10, 2008 (GlobeNewswire via COMTEX) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, has received the 2008 Emerging Technology Award for Biotechnology from the Silicon Valley/San Jose Business Journal. BiPar was selected as the first place winner in the biotechnology category for the company's pioneering work with poly (ADP-ribose) polymerase (PARP) inhibitors, a targeted therapeutic approach to treating triple negative breast and other solid tumor cancers by preventing cancer cells from repairing their own damaged DNA.
"We are honored to receive the 2008 Emerging Technology Award in Biotechnology," said Hoyoung Huh, M.D., Ph.D., president and chief executive officer of BiPar Sciences. "At BiPar, we are focused on developing novel PARP inhibitors to treat patients with the most difficult-to-treat cancers. We are thrilled that our innovative work in DNA-repair technology continues to be recognized as an important new therapeutic modality in cancer."
The award was presented to BiPar during a December 4 event held by the Silicon Valley/San Jose Business Journal at the Computer History Museum in Mountain View, California. The Silicon Valley/San Jose Business Journal established the annual "Emerging Technology" awards to recognize the innovations and significant accomplishments of technology-oriented companies in Silicon Valley. The awards honor companies in 13 categories that are making valuable progress in the advancement of current technologies or are on the cutting edge in pursuing new and emerging technologies. Profiles of the award winners and finalists were included in the December 5 issue of the Silicon Valley/San Jose Business Journal.
About BiPar Sciences and BSI-201
BiPar Sciences, Inc. is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to address unmet needs of cancer patients. The company's lead product candidate is BSI-201, which is in Phase 2 testing for triple negative breast cancer, ovarian cancer and other malignancies. BSI-201 is a poly (ADP-ribose) polymerase (PARP) inhibitor, a targeted approach to treating solid tumors by preventing cancer cells from repairing damaged DNA, ultimately causing the cancer cells to die. The company is also conducting preclinical studies on two additional compounds, BSI-401 (PARP inhibitor) and BSI-302 (anti-tubulin program). BiPar Sciences is privately held with headquarters in Brisbane, California. For more information, please visit www.biparsciences.com.